Drug intelligence / Profile preview

paclitaxel + carboplatin + topotecan

Development stage
Phase 3
Lead developer
Fox Chase Cancer Center
Modality
Small Molecules
Administration
Intravenous
01

Overview

This combination chemotherapy regimen consists of paclitaxel, carboplatin, and topotecan, and was specifically evaluated by the Fox Chase Cancer Center in a Phase II clinical trial. The protocol involves the administration of high-dose chemotherapy followed by peripheral blood stem cell (PBSC) transplantation to rescue the bone marrow from severe myelosuppression. Paclitaxel acts as a microtubule-stabilizing agent that inhibits mitosis, carboplatin is a platinum-based DNA alkylating agent that induces apoptosis through DNA cross-linking, and topotecan is a topoisomerase I inhibitor that causes lethal DNA strand breaks. This intensive approach was designed to treat extensive-stage small cell lung cancer (SCLC) and carcinoma of unknown primary, aiming to overcome drug resistance in metastatic settings.

Other names
High-dose paclitaxel, carboplatin, and topotecan with PBSC supportPaclitaxel-Carboplatin-Topotecan combination
02

Targets

DNATUBB (Tubulin (alpha and beta subunits))TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on paclitaxel + carboplatin + topotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paclitaxel + carboplatin + topotecan.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call